A descriptive study of persistent oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer

Supportive Care in Cancer

Volumn 22, Issue 2, 2014, Pages 513-518

  Vatandoust, Sina ^a,e   Joshi, Rohit ^a   Pittman, Kenneth B ^b   Esterman, Adrian ^c   Broadbridge, Vy ^b   Adams, Jacqueline ^a   Singhal, Nimit ^a   Yeend, Susan ^b   Price, Timothy Jay ^d  

^a LYELL MCEWIN HOSPITAL   (Australia)

^b QUEEN ELIZABETH HOSPITAL   (Australia)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e FLINDERS UNIVERSITY   (Australia)

Author keywords

Antineoplastic agents; Antineoplastic combined chemotherapy protocols; Colonic neoplasms; Colorectal neoplasms; Neurotoxicity syndromes; Oxaliplatin; Rectal neoplasms

Indexed keywords

CAPECITABINE; FLUOROURACIL; OXALIPLATIN;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; COLORECTAL CANCER; DAILY LIFE ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUESTIONNAIRE; RETROSPECTIVE STUDY; TREATMENT DURATION; VERY ELDERLY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROTOXICITY SYNDROMES; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVOUS SYSTEM DISEASES; QUESTIONNAIRES;

EID: 84896044847     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-013-2004-3     Document Type: Article

References (38)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69-90
2. Center MM, Jemal A, Smith RA, Ward E (2009) Worldwide variations in colorectal cancer. CA Cancer J Clin 59(6):366-378
3. Edwards BK, Ward E, Kohler BA et al (2010) Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116(3):544-573
4. Jemal A, Center MM, Desantis C, Ward EM (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res cosponsored by the Am Soc Prev Oncol 19(8):1893-1907
5. Andre T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Eng J Med 350(23):2343-2351 (Pubitemid 38702845)
6. De Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol 18(16):2938-2947 (Pubitemid 30644117)
7. Grothey A, Sargent D, Goldberg RM, Schmoll HJ (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol Off J Am Soc Clin Oncol 22(7): 1209-1214 (Pubitemid 41079833)
8. Kuebler JP, Wieand HS, O'connell MJ et al (2007) Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol Off J Am Soc Clin Oncol 25(16):2198-2204 (Pubitemid 46954643)
9. Cunningham D, Starling N, Rao S et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Eng J Med 358(1):36-46
10. Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Eng J Med 364(19): 1817-1825
11. Grothey A (2003) Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 30(4 Suppl 15):5-13
12. Argyriou AA, Polychronopoulos P, Iconomou G, Chroni E, Kalofonos HP (2008) A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev 34(4):368-377
13. Saif MW, Reardon J (2005) Management of oxaliplatin-induced peripheral neuropathy. Ther Clin Risk Manag 1(4):249-258
14. Jamieson SM, Liu J, Connor B, Mckeage MJ (2005) Oxaliplatin causes selective atrophy of a subpopulation of dorsal root ganglion neurons without inducing cell loss. Cancer Chemother Pharmacol 56(4):391-399 (Pubitemid 41095402)
15. Scuteri A, Galimberti A, Ravasi M et al (2010) NGF protects dorsal root ganglion neurons from oxaliplatin by modulating JNK/Sapk and ERK1/2. Neurosci Lett 486(3):141-145
16. Ta LE, Espeset L, Podratz J, Windebank AJ (2006) Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology 27(6):992-1002 (Pubitemid 44838955)
17. Grothey A (2005) Clinical management of oxaliplatin-associated neurotoxicity. Clin Color Cancer 5(Suppl 1):S38-S46
18. Andre T, Boni C, Navarro M et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol Off J Am Soc Clin Oncol 27(19):3109-3116
19. Park SB, Lin CS, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC (2011) Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist 16(5): 708-716
20. Denlinger CS, Barsevick AM (2009) The challenges of colorectal cancer survivorship. J Nat Compr Cancer Netw JNCCN 7(8):883-893, quiz 894
21. Calhoun EA, Welshman EE, Chang CH et al (2003) Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc 13(6):741-748 (Pubitemid 38235217)
22. Huang HQ, Brady MF, Cella D, Fleming G (2007) Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc 17(2):387-393 (Pubitemid 46426765)
23. Land SR, Kopec JA, Cecchini RS et al (2007) Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol Off J Am Soc Clin Oncol 25(16):2205-2211 (Pubitemid 46954644)
24. Cassidy J, Misset JL (2002) Oxaliplatin-related side effects: characteristics and management. Semin Oncol 29(5 Suppl 15):11-20 (Pubitemid 35191037)
25. Combination chemotherapy after surgery in treating patients with high-risk stage II or stage III colorectal cancer: clinicaltrials.gov Identifier: NCT00749450. http://clinicaltrials.gov/ct2/show/NCT00749450. Accessed 25 August 2013
26. Koike H, Iijima M, Sugiura M et al (2003) Alcoholic neuropathy is clinicopathologically distinct from thiamine-deficiency neuropathy. Ann Neurol 54(1):19-29 (Pubitemid 36764978)
27. D'amour ML, Bruneau J, Butterworth RF (1991) Abnormalities of peripheral nerve conduction in relation to thiamine status in alcoholic patients. Can J Neurol Sci Le journal canadien des sciences neurologiques 18(2):126-128
28. Chopra K, Tiwari V (2012) Alcoholic neuropathy: possible mechanisms and future treatment possibilities. Br J Clin Pharmacol 73(3):348-362
29. Uwah AN, Ackler J, Leighton JC Jr, Pomerantz S, Tester W (2012) The effect of diabetes on oxaliplatin-induced peripheral neuropathy. Clin Color Cancer 11(4):275-279
30. Vincenzi B, Frezza AM, Schiavon G et al (2013) Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 21(5):1313-1319
31. Oguri T, Mitsuma A, Inada-Inoue M et al (2013) Genetic polymorphisms associated with oxaliplatin-induced peripheral neurotoxicity in Japanese patients with colorectal cancer. Int J Clin Pharmacol Ther 51(6):475-481
32. Gamelin L, Boisdron-Celle M, Delva R et al (2004) Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res Off J Am Assoc Cancer Res 10(12 Pt 1): 4055-4061 (Pubitemid 38812481)
33. Wen F, Zhou Y, Wang W et al (2013) Ca/Mg infusions for the prevention of oxaliplatin-related neurotoxicity in patients with colorectal cancer: a meta-analysis. Annal Oncol Off J Eur Soc Med Oncol/ESMO 24(1):171-178
34. Grothey A, Nikcevich DA, Sloan JA et al (2011) Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol Off J Am Soc Clin Oncol 29(4):421-427
35. Khattak MA (2011) Calcium and magnesium prophylaxis for oxaliplatin-related neurotoxicity: is it a trade-off between drug efficacy and toxicity? Oncologist 16(12):1780-1783
36. Charles L. Loprinzi RQ, Shaker R. Dakhil, Louis Fehrenbacher, Philip J. Stella, Pamela J. Atherton, Drew K. Seisler, Rubina Qamar, Grant Carlton Lewis, Axel Grothey: Phase III randomized, placebo (PL)-controlled, double-blind study of intravenous calcium/magnesium (CaMg) to prevent oxaliplatin-induced sensory neurotoxicity (sNT), N08CB: an alliance for clinical trials in oncology study. http://meetinglibrary.asco.org/content/113106-132. Accessed 25 August 2013
37. Bennett BK, Park SB, Lin CS, Friedlander ML, Kiernan MC, Goldstein D (2012) Impact of oxaliplatin-induced neuropathy: a patient perspective. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 20(11):2959-2967
38. Sheikh K, Mattingly S (1981) Investigating non-response bias inmail surveys. J Epidemiol Community Health 35(4):293-296 (Pubitemid 12166934)